openPR Logo
Press release

3D Printing Positioned to Address Issues that have Prevented Wide Adoption of Microneedle Drug Delivery

01-03-2019 11:06 AM CET | Health & Medicine

Press release from: Greystone Research Associates

(Amherst, NH) – The promise of commercial microneedle drug delivery has been on the horizon for more than a decade. Like other compelling medical device innovations such as noninvasive glucose monitoring, the potential of the technology has yet to be realized due to the inability to solve the issues of reliable product performance from unit to unit and across a wide user population.

To fully address the unmet need these technologies represent, any successful solution must meet the requirements of patient self-administration, a set of use cases that include ease-of-use, reliability, consistent performance from patient-to-patient and dose-to-dose and minimal side effects. With only a few exceptions, microneedle drug delivery devices designed for patient self-use have not met these criteria, resulting in only a handful of drug-device products reaching the market.

Recently, developers have been turning to 3D printing as a way to create microneedles with the precision and repeatability that is needed to overcome the limitations of current production approaches. 3D printing – as known as additive manufacturing – is a family of almost a dozen methods that create three-dimensional structures from precise data sources such as CAD files to exact dimensions and spatial layouts. This methodology is the foundation for the repeatability and precision that has been missing in most legacy microneedle production approaches and which makes the technology well-positioned to break through the limitations that have gated the large-scale production of devices for the general population.

Another important aspect of additive manufacturing relative to legacy microneedle methods is the initial publication of guidelines that represent what may be considered as standardization. Legacy approaches have been proprietary and specific to the producer, making comparisons between and among microneedle devices extremely difficult if not impossible. The issuance of final guidance by the FDA in the first quarter of 2018 is designed to instill best practices in device manufacturers considering or using 3D printing. The document takes into account the range of additive manufacturing processes that might be used in a particular design. It also addresses the need to document the multiple software programs that may be used at various stages of the process.

3D printed microneedle drug delivery is detailed in a new and comprehensive report researched and written by Greystone Research Associates. The report – 3D Printed Microneedle Drug Delivery: Technology, Products, Markets, Players and Forecasts - analyzes additive manufacturing technology for microneedles and the current landscape for 3D printed microneedles. The report includes analysis of competitive factors, therapeutic markets, supply chain factors, and the product activities of sector participants.

More information is available at

Source: Greystone Research Associates

About Greystone

Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.


Mark Smith
Greystone Research Associates
98 Route 101A
Amherst, NH 03031 USA
Voice: 603-595-4340

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release 3D Printing Positioned to Address Issues that have Prevented Wide Adoption of Microneedle Drug Delivery here

News-ID: 1466882 • Views: 197

More Releases from Greystone Research Associates

Seeking to Capitalize on New Device Technology Drug Companies are Reformulating …
(Amherst, NH) – As the pace of competition increases within the pharmaceutical and biotech industries, the concept of life cycle management is becoming a key component of drug product management. Much of the recent emphasis in this area has centered on efforts to extend patent rights protection. While reformulation has been and is an important approach, efforts to prolong IP benefits have only recently involved IV-to-SC drug re-engineering. This migration
Antibacterial Treatments that don’t Rely on Antibiotics Winding their way thro …
(Amherst, NH) – As bacteria grow resistant to conventional antibiotics, alternatives are being investigated, including antibodies, probiotics, bacteriophages, and antimicrobial peptides. The quest to replace the current generation of antibiotics is complicated by the methods that bacteria have acquired to evade attempts to destroy them – methods often referred to a virulence factors. A microorganism can possess a wide array of virulence factors. They may only express these virulence factors when
Analysis of the Oncology Drug Pipeline Reveals Evolving Therapy Correlations and …
(Amherst, NH) – The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from
For Injectable Drugs Wireless Connectivity Allows Caregivers to Manage Patients …
(Amherst, NH) – The growing emphasis on drug self-administration is having a major impact on the pharmaceutical industry. The aging population and managed care initiatives are major forces driving the growth of home healthcare, a trend that includes the self-administration of drug therapies for chronic conditions such as diabetes, arthritis and hormone replacement therapy. This trend is creating an increased demand for medical devices that are patient-friendly and cost-effective. Much

All 5 Releases

More Releases for Amherst

Drug Companies Re-positioning Intravenous Drugs for Subcutaneous Delivery
(Amherst, NH) – The number of drugs based on biologicals continues to grow at an increasingly rapid rate. Because of their physical properties and the relatively high administration volumes often required to achieve the desired therapeutic effect, the majority are developed and launched for intravenous administration. This is creating a burgeoning demand for infusion facilities, personnel and equipment. The relative complexity, costs and patient logistics associated with IV infusion relative
Intradermal Drug Delivery Gaining Momentum as Technology and Benefits Converge
(Amherst, NH) – Evolution in drug delivery device design is changing the way a growing number of therapeutic substances are administered. This trend is being fostered by the desire by patients for more user friendly methods for self-medicating, and by the need for safer, more reliable drug products that improve compliance. For drugs capable of being administered across the skin, intradermal delivery is viewed as an approach that addresses these
Circulating Tumor Cells Spawning Diagnostic Tools to Guide Caregivers in Cancer …
(Amherst, NH) – Circulating tumor cells (CTCs) were first discovered more than a century ago. Because they originate from a malignant mass, they can carry useful information for clinicians with regard to the efficacy of treatments or to changes occurring within the tumor as a result of active treatment. The absence of a simple way to isolate and detect CTCs coupled with the lack of a clear understanding of the
New Aircraft Designs Creating Opportunities for High Performance Aerospace Coati …
(Amherst, NH) – As aerospace manufacturers and their engineering teams push the design envelope to create aircraft with better fuel efficiency and lower maintenance requirements, they are relying increasingly on engineered materials for a growing list of structural and non-structural elements and components. This trend is changing the way aircraft are developed, produced and maintained. It’s also presenting opportunities for specialty materials suppliers with products that can improve production
Drug Delivery Coatings Creating Opportunities for Developers and Practitioners
(Amherst, NH) – Advances in coating technology have given rise to a new generation of coating formulations that can reliably deliver therapeutic substances from the surface of an implanted medical device. In currently approved products, these devices provide a primary function, with the drug contributing therapeutic benefit that improves patient outcomes. Currently more than two dozen companies are pursuing specialty coatings capable of delivering APIs. These participants are exploring a
Adros Energy Expands Clean Energy Business with Energy Audit Services and opens …
Adros Energy; a leading green energy company in New England, announced today that they are opening a new headquarters in Amherst, NH after a successful 1st year of operation in the renewable energy market. The company was founded in January of 2009 and has found success during the incubation period of the company. The infrastructure building of the company in 2009 includes: • Revenue generation from its solar PV,